ALPHA-GLUCOSIDASE INHIBITORS















  • Average baseline A1C not reported
  • Length of studies not reported
  • Reference [1]
Acarbose (Aca) monotherapy in placebo-controlled trials in type two diabetics
Aca 25 mg 3 times a day
(N=110)
Aca 50 mg 3 times a day
(N=131)
Aca 100 mg 3 times a day
(N=244)
HgA1C (%)
(difference from placebo)
-0.44% -0.77% -0.74%

  • Average baseline A1C ∼ 8.3%
  • Average baseline 1 hr PP blood sugar ∼ 269mg/dl
  • Reference [1]
Acarbose (Aca) added to metformin (≥ 2000mg/day) in a 6 month placebo-controlled trial (N=147)
Placebo + metformin Aca 50 - 100 mg 3 times a day + metformin
HgA1C (%)
(average change from baseline at 6 months)
+0.08% -0.57%
1 hour postprandial blood sugar (mg/dl)
(average change from baseline at 6 months)
+3.3 -31

  • Average baseline A1C not reported
  • Number of patients in study not specified
  • Reference [2]
Miglitol (Mig) monotherapy 14 week, placebo-controlled trial
Placebo
Mig 50 mg 3 times a day Mig 100 mg 3 times a day
HgA1C (%)
(average change from baseline at 14 weeks)
+0.47% -0.22% -0.28%
1 hour postprandial blood sugar (mg/dl)
(average change from baseline at 14 weeks)
+15 -52 -59




Reference [1,2,7,9]
GI side effect Frequency (% of patients)
Flatulence 40 - 70%
Diarrhea 30%
Abdominal pain 10-20%